- Home
- XERS vs EYPT Comparison
XERS vs EYPT Comparison
Compare XERS & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XERS
- EYPT
- Stock Information
- Founded
- XERS 2005
- EYPT 1987
- Country
- XERS United States
- EYPT United States
- Employees
- XERS N/A
- EYPT N/A
- Industry
- XERS Biotechnology: Pharmaceutical Preparations
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- XERS Health Care
- EYPT Industrials
- Exchange
- XERS Nasdaq
- EYPT Nasdaq
- Market Cap
- XERS 526.3M
- EYPT 427.9M
- IPO Year
- XERS 2018
- EYPT 2005
- Fundamental
- Price
- XERS $4.24
- EYPT $7.13
- Analyst Decision
- XERS Strong Buy
- EYPT Strong Buy
- Analyst Count
- XERS 4
- EYPT 8
- Target Price
- XERS $5.75
- EYPT $25.71
- AVG Volume (30 Days)
- XERS 2.4M
- EYPT 830.5K
- Earning Date
- XERS 03-06-2025
- EYPT 03-05-2025
- Dividend Yield
- XERS N/A
- EYPT N/A
- EPS Growth
- XERS N/A
- EYPT N/A
- EPS
- XERS N/A
- EYPT N/A
- Revenue
- XERS $203,070,000.00
- EYPT $43,273,000.00
- Revenue This Year
- XERS $20.47
- EYPT N/A
- Revenue Next Year
- XERS $19.35
- EYPT N/A
- P/E Ratio
- XERS N/A
- EYPT N/A
- Revenue Growth
- XERS 23.89
- EYPT N/A
- 52 Week Low
- XERS $1.69
- EYPT $5.54
- 52 Week High
- XERS $4.50
- EYPT $24.37
- Technical
- Relative Strength Index (RSI)
- XERS 70.54
- EYPT 56.25
- Support Level
- XERS $3.59
- EYPT $5.54
- Resistance Level
- XERS $4.50
- EYPT $6.57
- Average True Range (ATR)
- XERS 0.25
- EYPT 0.59
- MACD
- XERS 0.03
- EYPT 0.15
- Stochastic Oscillator
- XERS 72.34
- EYPT 77.56
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.